Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD
|
|
- Ethel Banks
- 6 years ago
- Views:
Transcription
1 Original Research LUNG INFECTION Discrepant Results Between Pyrazinamide Susceptibility Testing by the Reference BACTEC 460TB Method and pnca DNA Sequencing in Patients Infected With Multidrug-Resistant W-Beijing Mycobacterium tuberculosis Strains* Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD Background: Mycobacterium tuberculosis strains belonging to the W-Beijing family have received broad clinical and public health attention because of their rapid worldwide spread and their frequent association with outbreaks, multidrug resistance, and treatment failures and relapses. Methods: The present study examined a large number of multidrug-resistant strain-w isolates (isolates of 29 patients) by susceptibility testing for pyrazinamide (PZA) using the reference BACTEC 460TB method (Becton Dickinson Diagnostic Instrument Systems; Sparks, MD) and also by DNA sequencing of the pnca gene. Results: We found that despite of the presence of a strain W-specific Thr47Ala in the pnca gene, all strains showed susceptibility to PZA in the reference BACTEC 460TB system due to their higher minimum inhibitory concentrations (relative to BACTEC 460TB PZA-susceptible strains). Conclusions: Our results suggest that the current radiometric reference method cannot reproducibly detect PZA resistance in patients infected with W-Beijing strains. Therefore, PZA susceptibility testing should instead be based on analysis of the pnca gene for resistanceassociated mutations. (CHEST 2007; 131: ) Key words: multidrug resistant; Mycobacterium tuberculosis; pnca; pyrazinamide; susceptibility testing; tuberculosis; W-Beijing genotype Abbreviations: INH isoniazid; MDR multidrug resistant; MIC minimal inhibitory concentration; PZA pyrazinamide; PZase pyrazinamidase; RFLP restriction fragment length polymorphism; RIF rifampin; XDR extensively drug resistant The worldwide increase of multidrug-resistant (MDR) tuberculosis (resistance at least to isoniazid [INH] and rifampin [RIF]) and extensively *From the Wadsworth Center (Drs. Somoskovi, Driscoll, and Salfinger and Ms. Dormandy), New York State Department of Health, Albany, NY; Public Health Research Institute (Dr. Kreiswirth), Newark, NJ; and A.G. Holley State Hospital (Dr. Ashkin), Lantana, FL. This work was performed at the Wadsworth Center, New York State Department of Health, Albany, NY, and Public Health Research Institute, Newark, NJ. The authors have no financial relationship with a commercial entity that has an interest in the subject of this article. drug-resistant tuberculosis (XDR) [resistance to INH and RIF and at least three of the six main classes of second-line drugs] is one of the greatest threats to achieving control of global tuberculosis. 1 Manuscript received August 12, 2006; revision accepted September 13, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Max Salfinger, MD, Wadsworth Center, New York State Department of Health, PO Box 509, Albany, NY ; salfinger@wadsworth.org DOI: /chest CHEST / 131 / 2/ FEBRUARY,
2 Following multiple nosocomial outbreaks in New York City in the 1990s, a unique strain with specific phenotypic (MDR) and genetic characteristics was identified and named as strain W. 2 Another outbreak strain with similar molecular epidemiologic characteristics emerged in the Beijing province of China. 3 Genetically, these strains can be characterized by multiple (15 to 26) copies of IS6110 that have similar restriction fragment length polymorphism (RFLP) genotyping patterns ( 65%); a unique IS6110 insertion in the origin of replication; and a specific spacer oligotype (spoligotype) lacking spacers 1 through 34 in the direct-repeat chromosomal locus of Mycobacterium tuberculosis. 2 4 Recently, strains bearing these characteristics have been classified into a large phylogenetic lineage called the W- Beijing lineage. 4 Since their discovery, members of the W-Beijing family have received broad clinical and public health attention because of their rapid worldwide spread and their frequent association with outbreaks, multidrug resistance, treatment failures, and relapses. 5,6 Immunologic studies 7 with animals have also identified specific pathogenic properties for these strains. Specifically, W-Beijing strains exhibit a higher virulence through their elicitation of a less sustained tumor necrosis factor- response from host macrophages, a weaker protective T-helper type 1 cell response, a more advanced and extensive pneumonia, and significantly higher mortality compared to M tuberculosis H37Rv in a BALB/c mouse model. 7 In addition, patients with W-Beijing strain infections often show fever that is unrelated to disease severity and toxicity. 8 Materials and Methods Between 1998 and 2005, a total of 211 MDR tuberculosis cases were reported in New York City. M tuberculosis strains obtained from 29 patients (13.7%) with MDR tuberculosis that were sent for characterization and drug susceptibility testing to the Clinical Mycobacteriology Laboratory at the Wadsworth Center, New York State Department of Health, during this period were included in the present study. Spoligotyping, a polymerase chain reaction-based genotyping method that detects 43 known spacer sequences that are interspersed between the direct repeats in the genomic repeat region of M tuberculosis, was performed with a commercially available kit (Isogen Bioscience BV; Maarssen, the Netherlands) according to the instructions of the manufacturer. 9 IS6110 RFLP fingerprinting was performed according to a standardized protocol as described previously. 10 The IS6110 fingerprint patterns of the examined strains were analyzed using software (Bionumerics version 3.0; Applied Maths; Austin, TX) as described earlier. 10 Routine testing for drug susceptibility by the radiometric BACTEC 460TB system (Becton Dickinson Diagnostic Instrument Systems; Sparks, MD) was performed on all isolates as described earlier. 11 In order to determine the level of pyrazinamide (PZA) susceptibility or resistance, on a subset (n 5) of the study isolates, the minimal inhibitory concentrations (MICs) for PZA were also determined in duplicates. In addition to the concentration of 100 g/ml at ph 6.0 for determination of drug resistance by the standard BACTEC protocol, the following PZA concentrations were also tested: 6.25 g/ml, 12.5 g/ml, 25 g/ml, and 50 g/ml. Drug resistance to first-line agents, with the exception of PZA, was confirmed by the agar proportion method using Middlebrook 7H10 agar. 12 In addition, resistance to INH, RIF, and PZA was confirmed by katg, rpob, and pnca sequencing, as reported earlier Primers Tb86 (5 -GAAACAGCGGCGCTGATCGT-3 ) and Tb87 (5 -GTTGTCCCATTTCGTCGGGG-3 ) flanking the region encoding amino acid Ser315 of katg were used to amplify a 209-base-pair product. 13 Primers rpo95. (5 -CCACCCAG- GACGTGGAGGCGATCACACCG-3 ) and rpo397 (5 -GT- CAACCCGTTCGGGTTCATCGAAACG-3 ) were used to amplify a 329-base-pair product, which included the relevant segment of rpob 14. Using two primers pnca-p1 5 -GCT-GGT- CAT-GTT-CGC-GAT-CG-3 and pnca-p6 5 - GCT-TTG-CGG- CGA-GCG-CTC-CA 3, which flanked the entire pnca gene and its upstream promoter, we generated a 700-base-pair product from each isolate as described previously. 15 The same primers were used for DNA sequencing of both strands of the three genes, with an automated DNA sequencer (Applied Biosystems 3700; Applied Biosystems; Foster City, CA). The sequencing results were compared with the wild-type katg, prob, and pnca sequence from M tuberculosis H37Rv, for detection of mutations. The DNA sequencing was performed by the Molecular Genetics Core Facility at the Wadsworth Center. Results The genotyping results demonstrated that all 29 isolates were strain-w isolates (belonged to the Table 1 Characteristics of the 29 MDR Isolates Belonging to the W-Beijing Family Laboratory Tests Results BACTEC 460TB susceptibility testing results for INH, RIF, Resistant ethambutol, and streptomycin (ph 6.8) BACTEC 460TB susceptibility testing results for PZA (ph 6.0) Susceptible Spoligotyping (octal code) IS6110 RFLP genotyping W (15 isolates) and W-family* (14 isolates) rpob gene DNA sequencing His526Tyr (CAC to TAC) katg gene DNA sequencing Ser315Thr (ACC to ACA) pnca gene DNA sequencing Thr47Ala (ACC to GCC) *Including strains W1, W12, W33, W665, and W Original Research
3 W-Beijing family) [Table 1]. All of these isolates showed resistance to INH, RIF, ethambutol, and streptomycin, while all demonstrated susceptibility to PZA (Table 1). DNA sequencing identified mutations, resulting in amino acid change Ser315Thr (ACC to ACA) in the katg gene and amino acid change His526Tyr (CAC to TAC) in the rpob gene, in all 29 isolates (Table 1). Interestingly, sequencing of the pnca gene revealed a rare Thr47Ala (ACC to GCC) mutation in all isolates that had been associated with strain-w isolates in earlier studies (Table 1). 16 With regard to MIC testing, three of the five strains tested showed a MIC of 50 g/ml, and two of the five strains showed a MIC of 100 g/ml. Discussion PZA, a nicotinamide analog thought to target an enzyme involved in fatty acid synthesis, is a pro-drug; it is converted to its active form, pyrazinoic acid, by the mycobacterial enzyme pyrazinamidase (PZase). 17 PZA has an excellent sterilizing effect on semidormant tubercle bacilli and, when used in combination with RIF, shortens the treatment of tuberculosis patients from 1 year to 6 months. 17 Several previous studies have suggested that susceptibility testing of M tuberculosis to PZA is not always reliable. 17 Testing was initially hindered by the requirement that the medium have a ph of 5.5 in order for the drug to be active. 18 However, many M tuberculosis isolates will not grow at a low ph. Subsequently, a more simplified broth-based radiometric assay (BACTEC 460TB) using ph 6.0 was described. 19 This method resulted in well-defined differences between PZA-susceptible and PZA-resistant strains, and became the currently recommended assay. 12 However, poor growth at ph 6.0 can lead to inconclusive results in up to 3.5% of the strains with this method, as well. 20 Other studies, 21 which measured and compared PZase activity of PZA-susceptible and PZA-resistant strains with results obtained by the radiometric method, have shown that at least 0.8% of the strains that grew in the presence of PZA were PZase positive and, thus, were reported as falsely resistant in the radiometric assay. More recently, DNA sequencing of the gene encoding PZase (pnca) has proven to be a reliable predictor: 72 to 98% of the PZA-resistant clinical isolates tested by the radiometric assay carry a mutation in the structural gene or in the putative promoter region of the gene. 17 DNA sequencing of the pnca gene has been found to be an accurate assay (99.4% sensitivity) for predicting PZA susceptibility or resistance also in our laboratory, based on the testing of 236 PZA-susceptible and 172 PZA-resistant (in the BACTEC 460TB system) isolates. 22 Taken together, these various observations suggest that for some strains the radiometric assay is inaccurate. The issue of inconsistent and nonreproducible PZA susceptibility testing results can be even more problematic in patients with polyresistant tuberculosis; for them, the inclusion or exclusion of PZA frequently plays an important role in the therapy. 23 For the reasons listed above, combined with our detection of a Thr47Ala mutation in the strain-w isolates, we decided to revisit the susceptibility to PZA of this family. Using the reference radiometric method on a subset (n 5) of the study isolates, we determined the MICs for PZA. Interestingly, all five strains showed higher MICs than BACTEC 460TB PZA-susceptible strains but lower MICs than BACTEC 460TB PZA-resistant strains. 19 Similar results had been observed for three MDR strains that also carried the rare Thr47Ala pnca mutation. 24 In that study 24 two of the strains exhibited resistance to 100 g/ml of PZA, and the third strain was resistant to 800 g/ml of PZA. Thus, in two independent studies, 24 (including this study), a Thr47Ala mutation in pnca has been found to correlate with increased resistance to PZA, suggesting that the Thr47Ala allele results in a less active form of PZase and, consequently, resistance to PZA. Conclusions First, PZA is a key drug in the treatment of tuberculosis. PZA shortens the duration of treatment when used in combination with RIF, and patients receiving regimens that contain PZA have a lower bacteriologic relapse rate compared to patients treated with regimens without PZA. 25 However, it has been shown that PZA has a limited role in preventing drug resistance, 26 and recent studies 27,28 revealed that PZA resistance is common in MDR isolates from previously treated patients. Therefore, the accurate prediction of PZA resistance is essential when managing treatment failure of patients with MDR and/or XDR tuberculosis who were already exposed to this drug (Fig 1). Secondly, this is particularly true in the case of infection with a drug-resistant W-Beijing strain; for these strains, transmission of the disease is more rapid, treatment failures and relapses are more common, and the clinical presentation may be more severe than with non W-Beijing strains. Our results suggest that a more accurate and rapid PZA drug resistance assay is warranted: the current radiometric reference method may not reproducibly detect PZA resistance in patients infected with W-Beijing strains. Instead, PZA susceptibility testing should be CHEST / 131 / 2/ FEBRUARY,
4 Figure 1. Turnaround times for detection of W-Beijing strains and their drug resistance patterns in comparison with the rate of spread of tuberculosis if transmission is not interrupted by rapid detection of these strains. DNA sequencing of the katg and rpob genes enables the rapid identification of MDR and/or XDR strains. DNA sequencing of the pnca gene enables the rapid identification of MDR and or XDR strains W. Stick figures indicate the number of individuals with infection if drug resistance is not detected and/or treatment is not optimal based on analysis of the pnca gene for resistanceassociated mutations (Fig 1). To shorten the turnaround time for detection of PZA resistance in these patients, the clinical mycobacteriology laboratory community will need to implement the pnca sequencing assay for direct use on clinical specimens; such an adaptation will permit identification of PZA drug-resistant mutants within 24 to 48 h (Fig 1). Moreover, this novel screening approach will immediately identify strain-w isolates given that they carry the unique Thr47Ala allele. Finally, successful treatment of cases with MDR and/or XDR tuberculosis relies on the use of drugs that clinicians need to have confidence. The implication that a mutation may be present in certain strains that may render a drug inactive clinically is important in that the clinician may want to add other drugs that the strain demonstrates susceptibility to rather than rely on one that may have reduced or no activity. The clinical significance of the presence of such a mutation needs to be further explored in animal models and in clinical trials. However, clinicians should be aware of the presence of such mutations from a diagnostic standpoint (more rapid diagnosis of potential W-Beijing strains) as well as potential clinical implications. ACKNOWLEDGMENT: The authors wish to thank Keith Derbyshire for critical review of the manuscript, and the Molecular Genetics Core Facility of the Wadsworth Center for performing the sequencing analyses. References 1 Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, MMWR Morb Mortal Wkly Rep 2006; 55: Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996; 275: van Soolingen D, Qian L, de Haas PE, et al. Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995; 33: Kremer K, Glynn JR, Lillebaek T, et al. Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J Clin Microbiol 2004; 42: Glynn JR, Whiteley J, Bifani PJ, et al. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: Lan NT, Lien HT, Tung le B, et al. Mycobacterium tuberculosis Beijing genotype and risk for treatment failure and relapse, Vietnam. Emerg Infect Dis 2003; 9: Lopez B, Aguilar D, Orozco H, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003; 133: van Crevel R, Nelwan RH, de Lenne W, et al. Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment. Emerg Infect Dis 2001; 7: Kremer K, van Soolingen D, Frothingham R, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex 500 Original Research
5 strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol 1999; 37: Kurepina N, Likhoshvay E, Shashkina E, et al. Targeted hybridization of IS6110 fingerprints identifies the W-Beijing Mycobacterium tuberculosis strains among clinical isolates. J Clin Microbiol 2005; 43: Inderlied CB, Salfinger M. Antimycobacterial agents and susceptibility tests. In: Murray PR, Baron EJ, Pfaller MA, et al eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1999; National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes: approved standard. NCCLS document M24-A. Wayne, PA: National Committee for Clinical Laboratory Standards, Somoskovi A, Song Q, Mester J, et al. Use of molecular methods to identify the Mycobacterium tuberculosis complex (MTBC) and other mycobacterial species and to detect rifampin resistance in MTBC isolates following growth detection with the BACTEC MGIT 960 system. J Clin Microbiol 2003; 41: Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother 2005; 49: Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pnca mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: Sreevatsan S, Pan X, Zhang Y, et al. Mutations associated with pyrazinamide resistance in pnca of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997; 41: Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatful GF, Jacobs WR Jr, eds. Molecular genetics of mycobacteria. Washington, DC: ASM Press, 2000; Butler WR, Kilburn JO. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob Agents Chemother 1983; 24: Salfinger M, Reller LB, Demchuk B, et al. Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. Res Microbiol 1989; 140: Miller MA, Thibert L, Desjardins F, et al. Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test. J Clin Microbiol 1996; 34: Miller MA, Thibert L, Desjardins F, et al. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of BACTEC method with pyrazinamidase assay. J Clin Microbiol 1995; 33: Dormandy J, Forbes S, Kaswa MK, et al. Is pnca sequencing a valid assay to replace the reference BACTEC 460TB method for PZA susceptibility testing [abstract]? Paper presented at: 106th General Meeting of the American Society for Microbiology; May 22 24, 2006; Orlando, FL; C-334: Hewlett D Jr, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995; 273: Morlock GP, Crawford JT, Butler WR, et al. Phenotypic characterization of pnca mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis: second report; the results up to 24 months. Hong Kong Chest Service/BMJ Research Council. Tubercle 1982; 63: Mitchison DA. Mechanisms of the action of drugs in the short-course chemotherapy. Bull Int Union Tuberc 1985; 60: Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: Saravia JC, Appleton SC, Rich ML, et al. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: CHEST / 131 / 2/ FEBRUARY,
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos
Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious
More informationThe Molecular Epidemiology of Tuberculosis
The Molecular Epidemiology of Tuberculosis Barry N. Kreiswirth,, PhD Director, PHRI TB Center Airborne pathogen, Mycobacterium tuberculosis Slow grower; doubles 24hrs; 3-4 weeks to culture 3-4 weeks for
More informationWhat is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationMolecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis
Molecular Epidemiology of Tuberculosis Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Overview TB transmission and pathogenesis Genotyping methods Genotyping for clinical management
More informationDNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert
JCM Accepted Manuscript Posted Online 4 March 2015 J. Clin. Microbiol. doi:10.1128/jcm.03433-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 DNA sequencing for the confirmation
More informationCDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service
CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory
More informationPATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA
PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA DN Magana-Arachchi 1, AJ Perera 1, V Senaratne 2 and NV Chandrasekharan
More informationPhenotypic Characterization of pnca Mutants of Mycobacterium tuberculosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2000, p. 2291 2295 Vol. 44, No. 9 0066-4804/00/$04.00 0 Phenotypic Characterization of pnca Mutants of Mycobacterium tuberculosis GLENN P. MORLOCK, 1 * JACK
More informationAnti-tuberculosis drug resistance in the world and rapid diagnosis of tuberculosis
Anti-tuberculosis drug resistance in the world and rapid diagnosis of tuberculosis Chiyoji ABE acquired drug resistance primary drug resistance 10 10 HIV 1 3 INHRFP MDR-TB DOTSDirectly Observed Treatment,
More informationDNA FINGERPRINTING. Barry N. Kreiswirth, PhD Director, PHRI TB Center
DNA FINGERPRINTING Barry N. Kreiswirth, PhD Director, PHRI TB Center Molecular Epidemiology Local Epidemiology Are M. tuberculosis isolates recovered from localized cases of disease the same or different
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationHigh Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India
BRIEF REPORT High Incidence of the Beijing Genotype among Multidrug-Resistant Isolates of Mycobacterium tuberculosis in a Tertiary Care Center in Mumbai, India Deepak Almeida, 1 Camilla Rodrigues, 2 Tester
More informationMultidrug resistance (MDR) epitomises. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
Eur Respir J 2009; 33: 368 374 DOI: 10.1183/09031936.00089808 CopyrightßERS Journals Ltd 2009 Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationRapid Diagnosis of Extensively Drug-Resistant Tuberculosis by Use of a Reverse Line Blot Hybridization Assay
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2546 2551 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.02511-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Rapid Diagnosis
More informationDRUG RESISTANCE IN TUBERCULOSIS
DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican
More informationHarmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis
Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There
More informationMycobacterium tuberculosis and Molecular Epidemiology: An Overview
Journal of Microbiology Research 2014, 4(6A): 25-31 DOI: 10.5923/s.microbiology.201401.04 Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Asho Ali Department of Biology, King Abdul Aziz
More informationResearch Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal
Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant
More informationTuberculosis Disparity Between US-born African-Americans and Caucasians in Houston:
Tuberculosis Disparity Between US-born African-Americans and Caucasians in Houston: A population-based study Jose A. Serpa 1, M.D.; Larry D. Teeter 2, Ph.D., James M. Musser 2, M.D., Ph.D. and Edward A.
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationPatterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea
ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.0042 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2018;81:222-227 Patterns of rpoc Mutations in -Resistant Mycobacterium tuberculosis Isolated
More informationPyrazinamide resistance among South African multi-drug resistant Mycobacterium tuberculosis ACCEPTED
JCM Accepts, published online ahead of print on 7 August 008 J. Clin. Microbiol. doi:0.8/jcm.00973-08 Copyright 008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMulti-clonal origin of macrolide-resistant Mycoplasma pneumoniae isolates. determined by multiple-locus variable-number tandem-repeat analysis
JCM Accepts, published online ahead of print on 30 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.00678-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Multi-clonal origin
More informationAcknowledgements. Transparency Declaration. Pyrazinamide resistance in multidrugresistant Mycobacterium tuberculosis isolates in Japan.
1164 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI Acknowledgements We thank the members of the TB Task Force of Greater Lisbon and its Fast and Faster Track TB Programmes for
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationReceived 6 May 2006/Returned for modification 2 June 2006/Accepted 23 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 76 80 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.00951-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative Evaluation
More informationThe treatment of patients with initial isoniazid resistance
The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background
More informationEvaluation of the Microscopic-Observation. Drug-Susceptibility Assay Drugs Concentration for Detection Of Multidrug-Resistant Tuberculosis
Evaluation of the Microscopic-Observation Drug-Susceptibility Assay Drugs Concentration for Detection Of Multidrug-Resistant Tuberculosis ABSTRACT New diagnostic tools are urgently needed to interrupt
More informationWELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears
Lab Talk: What a Lab Talk: What a Max Salfinger, MD, FIDSA, FAAM Executive Director, Advanced Diagnostic Laboratories Laboratory Director, Mycobacteriology & Pharmacokinetics National Jewish Health Lisa
More informationSpoligotyping of Mycobacterium tuberculosis Isolates from Pakistan Reveals Predominance of Central Asian Strain 1 and Beijing Isolates
JOURNAL OF CLINICAL MICROBIOLOGY, May 2006, p. 1763 1768 Vol. 44, No. 5 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.5.1763 1768.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationOverview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing
Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01495.x Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katg: a decade of experience
More informationReceived 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013
Epidemiol. Infect. (2014), 142, 1328 1333. Cambridge University Press 2013 doi:10.1017/s0950268813002409 SHORT REPORT Characterization of multi-drug resistant Mycobacterium tuberculosis from immigrants
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationA Rapid and Sensitive Chip-based Assay for Detection of rpob Gene Mutations Conferring Rifampicin Resistance in Mycobacterium tuberculosis (TB).
A Rapid and Sensitive Chip-based Assay for Detection of rpob Gene Mutations Conferring Rifampicin Resistance in Mycobacterium tuberculosis (TB). Wanyuan Ao, Steve Aldous, Evelyn Woodruff, Brian Hicke,
More informationJAC Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex
Journal of Antimicrobial Chemotherapy (2000) 46, 571 575 JAC Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex Pascale Bemer-Melchior a *, André
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationWhite Paper Application
White Paper Application Project Title: Whole genome sequencing of clinical strains of Mycobacterium tuberculosis Authors: David Alland, Jerrold Ellner, Susan Dorman, Moses Joloba, Clifton Barry Primary
More informationMulti-drug Resistant Tuberculosis in Rajshahi District
TAJ December 2005; Volume 18 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Original Article Multi-drug Resistant Tuberculosis in Rajshahi District M Wasim Hussain, 1 M Azizul
More informationTuberculosis Elimination, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
ORIGINAL ARTICLE 10.1111/j.1469-0691.2007.01711.x Association of specific mutations in katg, rpob, rpsl and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia
More informationPrevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients
Journal of Infection (2006) 53, 331e336 www.elsevierhealth.com/journals/jinf Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients Parissa
More informationTB Laboratory Services
TB Laboratory Services Max Salfinger, MD, FIDSA,FAAM Co-Lead, DrPH Laboratory Concentration University of South Florida, College of Public Health max@health.usf.edu http://health.usf.edu/publichealth/
More informationSpread of Strain W, a Highly Drug-Resistant Strain of Mycobacterium tuberculosis, Across the United States
85 Spread of Strain W, a Highly Drug-Resistant Strain of Mycobacterium tuberculosis, Across the United States Tracy B. Agerton, Sarah E. Valway, Richard J. Blinkhorn, Kenneth L. Shilkret, Randall Reves,
More informationEmergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli
CHEST Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli Original Research Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran Ali Akbar Velayati,
More informationTransmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University
Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationOUT-TB Web. Ontario Universal Typing of Tuberculosis: Surveillance and Communication System
OUT-TB Web Ontario Universal Typing of Tuberculosis: Surveillance and Communication System Dr. Frances Jamieson, Ontario Public Health Laboratories November 30 th, 2009 Tuberculosis : A Global Problem
More informationKekkaku Vol. 79, No. 11: ,
Kekkaku Vol. 79, No. 11:625-630, 2004 625 Reproducibility of MGIT 960 AST/M.Tomita et al. 627 Table 2 BACTEC MGIT 960 AST set inoculum from positive MGIT culture ( n=15) Table 3 Days required for BACTEC
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationAntimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018
Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million
More informationActivity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
Indian J Med Res 136, November 2012, pp 808-814 Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis Zahoor Ahmad 1,*, Sandeep Tyagi 1, Austin Minkowski
More informationDepartment of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
Indian J Med Res 135, May 2012, pp 756-762 Variations in the occurrence of specific rpob mutations in rifampicinresistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in
More informationTransmission of multidrug-resistant tuberculosis in a low-incidence setting, Switzerland, 2006 to 2012
Research articles Transmission of multidrug-resistant in a low-incidence setting, Switzerland, 2006 to 2012 A Somoskovi (asomoskoevi@imm.uzh.ch) 1, P Helbling 2, V Deggim 1, R Hömke 1, C Ritter 1, E C
More informationAspirin antagonism in isonizaid treatment of tuberculosis in mice ACCEPTED. Department of Molecular Microbiology & Immunology, Bloomberg School of
AAC Accepts, published online ahead of print on 4 December 2006 Antimicrob. Agents Chemother. doi:10.1128/aac.01145-06 Copyright 2006, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationTuberculosis Transmission by Patients with Smear- Negative Pulmonary Tuberculosis in a Large Cohort in The Netherlands
MAJOR ARTICLE Tuberculosis Transmission by Patients with Smear- Negative Pulmonary Tuberculosis in a Large Cohort in The Netherlands Alma Tostmann, 1,2 Sandra V. Kik, 3,4 Nico A. Kalisvaart, 3 Maruschka
More informationRapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa
Journal of Antimicrobial Chemotherapy Advance Access published October 21, 2008 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dkn433 Rapid genotypic assays to identify drug-resistant Mycobacterium
More informationTB BASICS: PRIORITIES AND CLASSIFICATIONS
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.
More informationNEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM
Crosswalk of Proposed Revision to Standards Any standards not addressed here remain in effect. (changes are underlined) Practice 8 (TB S8): Smears Only Permit Category - Specimen Submission and Result
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationThe Efficacy of Genotype MTBDRplus Assay in Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates
The Efficacy of Genotype MTBDRplus Assay in Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates Singh Shruti S 1, Desai Pratibha B. 2 1,2 Department of
More informationRapid detection of multidrug-resistant tuberculosis
Eur Respir J 1997; 10: 1120 1124 DOI: 10.1183/09031936.97.10051120 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Rapid detection of multidrug-resistant
More informationLABORATORY METHODS: TUBERCULOSIS DIAGNOSIS
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE LABORATORY METHODS: TUBERCULOSIS DIAGNOSIS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe three laboratory
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationRapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008
Tuberculosis Updates for Clinicians San Antonio, Texas November 13, 2008 Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008 Rapid Diagnostic Techniques for Identifying
More informationRapid Diagnosis of Tuberculosis and Multidrug Resistance Using a MGIT 960 System
Original Article Clinical Microbiology Ann Lab Med 2012;32:264-269 ISSN 2234-3806 eissn 2234-3814 Rapid Diagnosis of Tuberculosis and Multidrug Resistance Using a MGIT 960 System Won-Jung Koh, M.D. 1,
More informationMolecular Characterization of Mycobacterium tuberculosis H37Rv/Ra Variants: Distinguishing the Mycobacterial Laboratory Strain
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2000, p. 3200 3204 Vol. 38, No. 9 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Molecular Characterization of Mycobacterium
More informationResearch Article Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted from the Mixed Infection and the Testing System
BioMed Research International Volume 2015, Article ID 651980, 7 pages http://dx.doi.org/10.1155/2015/651980 Research Article Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted
More informationMolecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria
Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis Dr Sahajal Dhooria What is drug resistant TB? Definitions MDR TB defined as resistance to isoniazid and rifampicin, with or without resistance
More informationTUBERCULOSIS AND MDR-TB IN THE NORTHERN EMIRATES OF UNITED ARAB EMIRATES: A 5-YEAR STUDY
TUBERCULOSIS AND MDR-TB IN THE UAE TUBERCULOSIS AND MDR-TB IN THE NORTHERN EMIRATES OF UNITED ARAB EMIRATES: A 5-YEAR STUDY Mansour AL-Zarouni 1, Nihar Dash 2, Mahar Al Ali 3, Fatma Al-Shehhi 1 and Debadatta
More informationThe authors assessed drug susceptibility patterns
Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division
More informationThe New England Journal of Medicine EXOGENOUS REINFECTION AS A CAUSE OF RECURRENT TUBERCULOSIS AFTER CURATIVE TREATMENT
EXOGENOUS REINFECTION AS A CAUSE OF RECURRENT TUBERCULOSIS AFTER CURATIVE TREATMENT ANNELIES VAN RIE, M.D., ROBIN WARREN, PH.D., MADELEINE RICHARDSON, M.SC., THOMAS C. VICTOR, PH.D., ROBERT P. GIE, M.D.,
More informationPredictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Eur Respir J 2009; 33: 1085 1094 DOI: 10.1183/09031936.00155708 CopyrightßERS Journals Ltd 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB K. Kliiman and
More informationThe Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida
The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida Calin B. Chiribau, 1 M-C. Rowlinson, 1 S.Crowe, 1 B. Jones, 1
More informationAugust 30, 1991 / 40(34);
August 30, 1991 / 40(34);585-591 Epidemiologic Notes and Reports Nosocomial Transmission of Multidrug-Resistant Tuberculosis Among HIV-Infected Persons -- Florida and New York, 1988-1991 During 1990 and
More informationLaboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients
Laboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients Max Salfinger Fogarty Workshop on TB/HIV Cali, Colombia - March 28, 2007 John E. Fogarty Bricklayer;
More informationThe ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory
The ABC s of AFB s Laboratory Testing for Tuberculosis Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory Laboratory TAT Goals Case Study Specimen Collection Testing Contact
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationClinical spectrum and standard treatment of tuberculosis
Clinical spectrum and standard treatment of tuberculosis Graham Bothamley Homerton University Hospital, London, UK 2 nd European Advanced Course in Clinical Tuberculosis 1 Plan of talk Why is there a clinical
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationGenotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province. Kgasha Matete Olga
Genotyping of Multidrug-Resistant Strains of Mycobacterium tuberculosis in the Limpopo Province by Kgasha Matete Olga DISSERTATION Submitted in fulfillment of the requirements for the degree of MASTER
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationLaboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationIn-vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and. sulfonamides, France
AAC Accepts, published online ahead of print on 23 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01683-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 In-vitro
More informationWSLH Testing and Surveillance Updates
WSLH Testing and Surveillance Updates Wisconsin Mycobacteriology Laboratory Network annual conference November 4, 2015, Madison, WI Updates Outline Collection and Transport Smear and Culture Nucleic Acid
More informationShah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED
/7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February
More informationWei-Lun Huang,* Ting-Lin Chi, Mei-Hua Wu, and Ruwen Jou*
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2502 2508 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00197-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationLaboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives
Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Marie-Claire Rowlinson, PhD D(ABMM) Calin Chiribau, PhD, MT(ASCP) Florida Bureau of Public Health Laboratories
More informationCharacteristics of Mycobacterium
Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to
More information